GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
A phase 1/2 trial of Pembrolizumab in melanoma and colorectal cancer, run by GeneMedicine Co., Ltd., now recruiting.
Overview
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06265025 by GeneMedicine Co., Ltd., with 125 participants planned, started 2024-02-20 and due to reach its primary completion in 2025-05-30. Interventions recorded: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C). Conditions listed: Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Cervical cancer, Pembrolizumab, Colorectal cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Melanoma, Pembrolizumab.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Melanoma, Pembrolizumab.
- TrialSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Colorectal cancer.
- TrialA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Shares Renal cell carcinoma, Melanoma, Colorectal cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab.
- PersonSamra Turajlić
Shares Renal cell carcinoma, Melanoma.
- TrialA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Shares Renal cell carcinoma, Pembrolizumab.